Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Operating Leases (2019 - 2025)

Sanofi's Operating Leases history spans 6 years, with the latest figure at $2.0 billion for Q4 2024.

  • For Q4 2024, Operating Leases fell 6.75% year-over-year to $2.0 billion; the TTM value through Dec 2024 reached $2.0 billion, down 6.75%, while the annual FY2024 figure was $2.1 billion, 6.05% down from the prior year.
  • Operating Leases for Q4 2024 was $2.0 billion at Sanofi, down from $2.2 billion in the prior quarter.
  • Across five years, Operating Leases topped out at $2.4 billion in Q4 2021 and bottomed at $1.1 billion in Q4 2020.
  • The 5-year median for Operating Leases is $2.0 billion (2024), against an average of $1.9 billion.
  • The largest annual shift saw Operating Leases skyrocketed 117.25% in 2021 before it decreased 19.45% in 2022.
  • A 5-year view of Operating Leases shows it stood at $1.1 billion in 2020, then surged by 117.25% to $2.4 billion in 2021, then fell by 19.45% to $1.9 billion in 2022, then increased by 12.44% to $2.2 billion in 2023, then dropped by 6.75% to $2.0 billion in 2024.
  • Per Business Quant, the three most recent readings for SNY's Operating Leases are $2.0 billion (Q4 2024), $2.2 billion (Q4 2023), and $1.9 billion (Q4 2022).